Full history for every metric is available with a Kvantra account
Promore Pharma AB (publ) (PROMO.ST)
Key financial summary
Financials in SEK| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | 1 | 2 | 4 | 0 | 0 | 0 | 0 |
| Operating profit | SEK m | -27 | -21 | |||||
| Net profit | SEK m | -8 | -32 | -29 | -30 | -27 | -27 | -21 |
| EPS reported | SEK | -56.12 | -0.36 | |||||
| Operating cashflow per share | SEK | -0.45 | -0.45 | |||||
| Capex per share | SEK | 0.00 | 0.00 | |||||
| FCF per share | SEK | -0.45 | -0.45 | |||||
| Free cash flow | SEK m | -27 | -22 | |||||
| Net debt | SEK m | -17 | -3 | |||||
| Book value equity | SEK m | 14 | - | |||||
| Book value per share | SEK | 0.23 | - | |||||
| Number of shares | m | 60.71 | 60.71 | |||||
| DPS (TTM paid) | SEK | 0.00 | 0.00 |
Financial summary
Financials in SEK| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 446.67 | 0.48 | |||||
| P/S LTM | x | 63,111.90 | 1,133.39 | |||||
| P/FCF LTM | x | -229.10 | -13.25 | |||||
| EV/EBITDA LTM | x | -234.22 | -16.53 | |||||
| EV/Sales LTM | x | 62,939.23 | 1,121.14 | |||||
| Earnings Yield LTM | % | -0.43% | -398.58% | |||||
| FCF Yield | % | -0.44% | -7.55% | |||||
| Quality | ||||||||
| ROE | % | -190.30% | -97.51% | |||||
| ROIC | % | -180.95% | -180.95% | |||||
| Operating margin | % | -26871.7% | -26871.7% | |||||
| Gross margin | % | -16005.1% | -16005.1% | |||||
| FCF/Sales | % | -27547.5% | -27547.5% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -76.26% | -42.44% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -38.20 | -31.04 | |||||
| Net Debt/EBITDA | x | 0.64 | 0.64 | |||||
| EBIT/Net interest | x | -1,662.69 | -1,662.69 | |||||
| Net debt/market cap | % | -0.27% | -1.08% | |||||
| Net debt/Equity | x | -1.22 | - | |||||
| Gross debt/equity | x | 0.05 | - | |||||
Company overview
Promore Pharma AB (publ) is a Swedish biopharmaceutical firm dedicated to advancing peptide-based drug therapies. The company's development pipeline features PXL01, currently undergoing Phase IIa studies for its potential in preventing post-surgical adhesions and scars, mitigating dermal scarring, and aiding hand tendon repair. Another key asset, LL-37, is engaged in Phase IIb clinical trials to address venous leg ulcers, stimulate the healing of persistent wounds, and treat diabetic foot ulcers. Additionally, Promore Pharma has partnered with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. Founded in 2002, the company, formerly known as Lipopeptide AB until its rebranding in January 2017, maintains its headquarters in Solna, Sweden.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Promore Pharma AB (publ) (PROMO.ST)
Promore Pharma AB (publ) is a Swedish biopharmaceutical firm dedicated to advancing peptide-based drug therapies. The company's development pipeline features PXL01, currently undergoing Phase IIa studies for its potential in preventing post-surgical adhesions and scars, mitigating dermal scarring, and aiding hand tendon repair. Another key asset, LL-37, is engaged in Phase IIb clinical trials to address venous leg ulcers, stimulate the healing of persistent wounds, and treat diabetic foot ulcers. Additionally, Promore Pharma has partnered with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. Founded in 2002, the company, formerly known as Lipopeptide AB until its rebranding in January 2017, maintains its headquarters in Solna, Sweden.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free